Celldex Therapeutics (NASDAQ:CLDX) Shares Down 5.5% - Should You Sell?

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report)'s stock price dropped 5.5% on Monday . The company traded as low as $20.06 and last traded at $20.10. Approximately 889,296 shares changed hands during trading, a decline of 5% from the average daily volume of 937,358 shares. The stock had previously closed at $21.26.

Analyst Ratings Changes

Several research analysts have recently commented on CLDX shares. Canaccord Genuity Group initiated coverage on Celldex Therapeutics in a research report on Monday, April 28th. They set a "buy" rating and a $64.00 price target for the company. The Goldman Sachs Group dropped their target price on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. HC Wainwright reissued a "buy" rating and set a $50.00 price target on shares of Celldex Therapeutics in a research report on Friday. Morgan Stanley cut their target price on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. Finally, UBS Group dropped their price target on shares of Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $50.90.

Celldex Therapeutics Trading Down 4.3%

The firm's fifty day moving average price is $19.43 and its 200-day moving average price is $21.71. The firm has a market cap of $1.35 billion, a price-to-earnings ratio of -7.91 and a beta of 1.33.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). The firm had revenue of $0.70 million for the quarter, compared to analysts' expectations of $1.08 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. On average, sell-side analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current year.

Institutional Trading of Celldex Therapeutics

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in shares of Celldex Therapeutics by 0.4% during the first quarter. Vanguard Group Inc. now owns 3,898,435 shares of the biopharmaceutical company's stock worth $70,757,000 after buying an additional 16,440 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Celldex Therapeutics by 23.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,557,136 shares of the biopharmaceutical company's stock valued at $89,890,000 after purchasing an additional 676,771 shares during the period. Point72 Asset Management L.P. lifted its position in shares of Celldex Therapeutics by 50.8% during the 4th quarter. Point72 Asset Management L.P. now owns 2,515,972 shares of the biopharmaceutical company's stock valued at $63,579,000 after acquiring an additional 847,264 shares during the period. Deep Track Capital LP purchased a new stake in Celldex Therapeutics during the fourth quarter worth $38,919,000. Finally, Rock Springs Capital Management LP increased its holdings in Celldex Therapeutics by 10.7% during the 4th quarter. Rock Springs Capital Management LP now owns 1,222,182 shares of the biopharmaceutical company's stock valued at $30,885,000 after acquiring an additional 118,404 shares in the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.